

Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome

Katrina Kesterson, MS^a, Zachary Nahmias, MD^b,
Jonathan R. Brestoff, MD, PhD^c,
Nancy D. Bodet, RN, JD^{b,d}, Andrew Kau, MD, PhD^e, and
Brian S. Kim, MD, MTR^{b,c,d,f}



Clinical Implications

- This case suggests that mast cell activation syndrome (MCAS) may underlie generalized chronic pruritus and therefore offers a novel therapeutic approach in this context.

TO THE EDITOR:

Mast cell activation syndrome (MCAS) is a newly recognized collection of disorders that typically involves multiple organ systems and symptoms can include flushing, pruritus, angioedema, and dermatographism.¹ These symptoms are unified by the fact that they can be explained by the effects of mast cell–derived factors such as histamine, leukotrienes, and prostaglandins on various tissues. The proposed criteria for MCAS include episodic signs and symptoms consistent with mast cell activation involving multiple organ systems, increased markers of mast cell activation, and an appropriate response to medications that target mast cell activation or their effector molecules.^{2–4} Markers of mast cell activation can include serum tryptase and/or urinary metabolites of mast cell–derived mediators such as histamine, prostaglandin D₂ (PGD₂), 11 β -PGF₂ α , and leukotriene E₄.^{2–4} Recent criteria indicate that certain markers of mast cell activation such as serum tryptase may be more specific than others and thus the role of various factors is still emerging in the MCAS literature.^{3,4} However, tests such as the prostaglandin metabolite 11 β -PGF₂ α may be useful when serum tryptase is inconclusive, and the results of prostaglandin metabolite tests can be used to guide therapy.² We present a case of generalized pruritus presenting in the setting of MCAS that was responsive to the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen.

A 72-year-old woman presented with an 18-month history of generalized pruritus associated with a rash. The medical history was notable for adult-onset asthma and allergic rhinitis. She was treated with the anti-IgE agent omalizumab, which predominantly blocks activity on mast cells and basophils. Although her asthma symptoms improved, her chronic itch persisted despite treatment with both omalizumab and antihistamines. Her initial numerical rating scale itch score was 6/10. The physical examination was notable for eczematous pink patches on the chest, back, and upper and lower extremities. A skin biopsy showed subacute spongiotic dermatitis with eosinophils and, thus, she was treated presumptively for atopic dermatitis. However, her itch was unresponsive to topical steroids, calcineurin inhibitors, and narrow-band ultraviolet B therapy.

Laboratory workup was notable for elevated eosinophils of 1.54 K/mL (reference range, 0–0.05 K/mL) but otherwise a normal complete blood cell count. In addition, electrolytes and renal, hepatic, biliary, and thyroid function test results were all within normal limits. C-reactive protein, erythrocyte sedimentation rate, IgE, and serum tryptase values were also within the normal range. Although serum tryptase is the most specific marker of mast cell activation, when inconclusive other urinary metabolites can be explored.² In light of high suspicion for MCAS, we obtained a 24-hour urine sample for 11 β -PGF₂ α and found that the patient's urinary concentration was 15,976 pg/mg Cr (reference range, <5,205 pg/mg Cr). Given her history of episodic allergic processes in the upper airways, lungs, and skin as well as her refractory pruritus and elevated urine 11 β -PGF₂ α value, a preliminary diagnosis of MCAS was made. The patient was started on ibuprofen 400 mg daily as needed given a history of exposure with no adverse reactions. Strikingly, she noted marked and rapid improvement in her itch (numerical rating scale itch score of 0/10) on increasing her dose to 800 to 1600 mg divided twice daily, which correlated with a reduction in urinary 11 β -PGF₂ α level to a normal level of 4713 pg/mg Cr (reference range, <5,205 pg/mg Cr). It was also noted that whenever she stopped taking ibuprofen, her itch would rapidly resume back to baseline levels (numerical rating scale itch score of 6/10).

PGD₂ and its metabolite 11 β -PGF₂ α can be useful diagnostic and therapeutic markers in MCAS.^{2–4} PGD₂ is synthesized via the cyclooxygenase pathway in mast cells and can cause vasodilation. In the liver and lungs, PGD₂ is converted to 11 β -PGF₂ α , which also retains biologic activity.⁵ PGD₂ may be selectively released by mast cells even in the absence of histamine, possibly explaining why antihistamines can be ineffective as in this patient.⁶ However, the precise mechanism of action of PGD₂ in generalized pruritus is unknown. Notwithstanding this, we hypothesized that inhibiting the cyclooxygenase pathway with an NSAID and blocking the synthesis of PGD₂ may alleviate symptoms of generalized pruritus in the setting of MCAS. Similarly, aspirin has previously been shown to abate generalized pruritus and flushing in this disease along with a reduction in urinary 11 β -PGF₂ α .⁷

This case highlights the importance of considering MCAS in a patient presenting with generalized pruritus in addition to other symptoms of mast cell activation. Although this patient failed multiple mast cell modulators (eg, antihistamines and omalizumab) with regard to her chronic pruritus, her symptoms did improve once she was treated with an NSAID. The identification of elevated urinary 11 β -PGF₂ α level played a critical role in her diagnosis and therapeutic outcome. Thus, this case underscores the potential benefits of considering MCAS in patients with generalized pruritus and other features of allergic disorders.

^aThe University of Tennessee Health Science Center College of Medicine, Memphis, Tenn

^bDivision of Dermatology, Department of Medicine, Washington University School of Medicine, St Louis, Mo

^cDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, Mo

^dCenter for the Study of Itch, Washington University School of Medicine, St Louis, Mo

^eDivision of Allergy and Immunology, Department of Medicine, Washington University School of Medicine, St Louis, Mo

^fDepartment of Anesthesiology, Washington University School of Medicine, St Louis, Mo

This study was supported by funding from the National Center for Advancing Translational Sciences Clinical and Translational Science Award (grant no. UL1TR000448), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant nos. K08AR065577 and R01AR070116), the American Skin Association, and the Doris Duke Charitable Foundation Clinical Scientists Development Award.

Conflicts of interest: The authors declare that they have no relevant conflicts of interest.

Received for publication March 12, 2018; revised March 12, 2018; accepted for publication March 13, 2018.

Available online March 23, 2018.

Corresponding author: Brian S. Kim, MD, MTR, 660 South Euclid Ave, Campus Box 8123, St Louis, MO 63110. E-mail: briankim@wustl.edu.

2213-2198

© 2018 American Academy of Allergy, Asthma & Immunology

<https://doi.org/10.1016/j.jaip.2018.03.002>

REFERENCES

1. Petra AI, Panagiotidou S, Stewart JM, Conti P, Theoharides TC. Spectrum of mast cell activation disorders. *Expert Rev Clin Immunol* 2014;10:729-39.
2. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. *Int Arch Allergy Immunol* 2012;157:215-25.
3. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. *J Allergy Clin Immunol* 2010;126:1099-104.
4. Akin C. Mast cell activation syndromes. *J Allergy Clin Immunol* 2017;140:349-55.
5. Liston TE, Roberts LJ II. Transformation of prostaglandin D2 to 9 alpha, 11 beta-(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 alpha, 11 beta-prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. *Proc Natl Acad Sci USA* 1985;82:6030-4.
6. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. *Int Arch Allergy Immunol* 2008;147:338-43.
7. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. *J Allergy Clin Immunol Pract* 2014;2:775-8.